Mirodenafil

Mirodenafil belongs to the drug class PDE5 inhibitors, which includes avanafil, sildenafil, tadalafil, udenafil, and vardenafil, and is the first-line treatment for erectile dysfunction. Developed by SK Chemicals Life Science, mirodenafil is marketed in Korea under the trade name Mvix, offered both as tablets (50 mg and 100 mg) and as orally dissolving films (50 mg).

Mirodenafil

Legal status
Legal status	US: Unscheduled; not FDA-approved Rx-only (KR)
Identifiers
IUPAC name 5-Ethyl-3,5-dihydro-2-[5-([4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl)-2-propoxyphenyl]-7-propyl-4H-pyrrolo[3,2-d]pyrimidin-4-one
CAS Number	862189-95-5 Y
PubChem CID	12001014
ChemSpider	10173481 N
UNII	504G362H0H
ChEBI	CHEBI:136049
CompTox Dashboard (EPA)	DTXSID50881265
Chemical and physical data
Formula	C26H37N5O5S
Molar mass	531.67 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCCc1cn(CC)c2c1[nH]c(nc2=O)c1c(OCCC)ccc(c1)S(=O)(=O)N1CCN(CC1)CCO
InChI InChI=1S/C26H37N5O5S/c1-4-7-19-18-30(6-3)24-23(19)27-25(28-26(24)33)21-17-20(8-9-22(21)36-16-5-2)37(34,35)31-12-10-29(11-13-31)14-15-32/h8-9,17-18,32H,4-7,10-16H2,1-3H3,(H,27,28,33) N Key:MIJFNYMSCFYZNY-UHFFFAOYSA-N N
NY (what is this?)  (verify)

Despite several clinical trials having been conducted,^[1][2][3] mirodenafil has not been approved for use in the United States by the U.S. Food and Drug Administration.